Deerfield Management’s Ascendis Pharma A/S ASND Stock Holding History

Deerfield Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-144,194	Closed	-$17M	–	99
2019 Q1	$17M	Sell	144,194 -360,904	-71%	-$31.6M	0.65%	47
2018 Q4	$31.6M	Buy	505,098 +185,098	+58%	+$11.6M	1.27%	30
2018 Q3	$22.7M	Sell	320,000 -162,467	-34%	-$11.2M	0.81%	44
2018 Q2	$32.1M	Hold	482,467	–	–	1.13%	33
2018 Q1	$31.6M	Sell	482,467 -306,533	-39%	-$17.2M	1.09%	31
2017 Q4	$31.6M	Sell	789,000 -61,000	-7%	-$2.22M	1.24%	29
2017 Q3	$30.8M	Buy	850,000 +430,547	+103%	+$12.4M	1.39%	23
2017 Q2	$11.6M	Sell	419,453 -509,773	-55%	-$13.5M	0.62%	47
2017 Q1	$26M	Sell	929,226 -120,774	-12%	-$3.05M	1%	36
2016 Q4	$21.3M	Buy	+1,050,000	New	+$21M	0.87%	37
2015 Q3	–	Sell	-20,859	Closed	-$369K	–	136
2015 Q2	$369K	Sell	20,859 -179,141	-90%	-$3.13M	0.01%	120
2015 Q1	$3.47M	Buy	+200,000	New	+$3.64M	0.11%	97

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Deerfield Management's ASND Position: Q2 2019 in Review

Deerfield Management sold out of Ascendis Pharma A/S (ASND) in Q2 2019, closing a stake of 144,194 shares — an estimated $17M sold.

Deerfield Management first reported a position in ASND in Q1 2015 and held it in 12 quarters. The position peaked at $32.1M in Q2 2018. 132 funds tracked by Wall St. Rank hold ASND as of Q2 2019.

Deerfield Management reported no remaining Ascendis Pharma A/S position as of Q2 2019 after selling out during the quarter.
Deerfield Management sold 144,194 Ascendis Pharma A/S shares in Q2 2019, an estimated $17M.
Deerfield Management first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 12 quarters.
Deerfield Management's Ascendis Pharma A/S position peaked at $32.1M in Q2 2018.
132 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2019.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.